Exclusive Option Agreement for NXP001 in Oncology

Cambridge, UK - 24th September 2020

Cambridge, UK – 24 September 2020: Nuformix plc (LSE:NFX) (“Nuformix” or “the Group”), a pharmaceutical development company focused on unlocking the therapeutic potential and value of known drugs to develop novel medicines to provide enhanced benefit, announces it has signed an exclusive option agreement with Oxilio Ltd (“Oxilio”).

Download News

Back to all News